Targeting of cancer stem/progenitor cells plus stem cell-based therapies: The ultimate hope for treating and curing aggressive and recurrent cancers

Panminerva Medica

Volumn 50, Issue 1, 2008, Pages 3-18

  Mimeault, M ^a   Batra, S K ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Adult stem cells; Gene therapy; Neoplastic stem cells; Regenerative medicine

Indexed keywords

BRAIN TUMOR; CANCER STEM CELL; DISEASE COURSE; HUMAN; LEUKEMIA; MELANOMA; NEOPLASM; PATHOLOGY; REVIEW; SARCOMA; STEM CELL TRANSPLANTATION; TUMOR RECURRENCE;

BRAIN NEOPLASMS; DISEASE PROGRESSION; HUMANS; LEUKEMIA; MELANOMA; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; NEOPLASMS, GLANDULAR AND EPITHELIAL; NEOPLASTIC STEM CELLS; SARCOMA; STEM CELL TRANSPLANTATION;

EID: 44949115149     PISSN: 00310808     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (210)

1. Brawley OW, Kramer BS. Cancer screening in theory and in practice. J Clin Oncol 2005;23:293-300.
2. van der Merwe DE, Oikonomopoulou K, Marshall J, Diamandis EP. Mass spectrometry: uncovering the cancer proteome for diagnostics. Adv Cancer Res 2006;96:23-50.
3. Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature 2007;445:851-7.
4. Tallman MS. Treatment of relapsed or refractory acute promyelocytic leukemia. Best Pract Res Clin Haematol 2007;20:57-65.
5. Zhou GB, Zhang J, Wang ZY, Chen SJ, Chen Z. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy. Philos Trans R Soc Lond B Biol Sci 2007;362:959-71.
6. Zheng X, Seshire A, Ruster B, Bug G, Beissert T, Puccetti E et al. Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RARalpha-positive leukemic stem cells. Haematologica 2007;92:323-31.
7. Jovanovic JV, Score J, Waghorn K, Cilloni D, Gottardi E, Metzgeroth G et al. Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA positive chronic eosinophilic leukemia. Blood 2007;109:4635-40.
8. Goldman J, Gordon M. Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter? Leuk Lymphoma 2006;47:1-7.
9. Mimeault M, Brand RE, Sasson AA, Batra SK. Recent advances on the molecular mechanisms involved in pancreatic cancer progression and therapies. Pancreas 2005;31:301-16.
10. Mimeault M, Batra SK. Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies. Carcinogenesis 2006;27:1-22.
11. Mimeault M, Batra SK. Recent advances on the significance of stem cells in tissue regeneration and cancer therapies. Stem Cells 2006;24:2319-45.
12. Mimeault M, Hauke R, Mehta PP, Batra SK. Recent advances on cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers. J Mol Cell Med 2007;11:981-1011.
13. Mimeault M, Hauke R, Batra SK. Stem cells - A revolution in therapeutics - Recent advances on the stem cell biology and their therapeutic applications in regenerative medicine and cancer therapies. Clin Pharmacol Ther 2007;82:252-64.
14. Mimeault M, Batra SK. Stem cell applications in disease research: Recent advances on stem cell and cancer stem cell biology and their therapeutic implications. In: Allen V. Faraday and Jonathon T. Dyer, editorsr. Progress in stem cell applications. New York: Nova Publisher; 2008 (In press)
15. Sato M, Shames DS, Gazdar AF, Minna JD. A translational view of the molecular pathogenesis of lung cancer. J Thorac Oncol 2007;2:327-43.
16. Copland M, Jorgensen HG, Holyoake TL. Evolving molecular therapy for chronic myeloid leukaemia - are we on target? Hematology 2005;10:349-59.
17. Copland M, Hamilton A, Elrick LJ, Baird JW, Allan EK, Jordanides N et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 2006;107:4532-9.
18. Mauro MJ. Defining and managing imatinib resistance. Hematology Am Soc Hematol Educ Program 2006;219-25.
19. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66
20. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005;5:275-84.
21. Milas L, Raju U, Liao Z, Ajani J. Targeting molecular determinants of tumor chemo-radioresistance. Semin Oncol 2005;32:S78-S81.
22. Nicolis SK. Cancer stem cells and "sternness" genes in neuro-oncology. Neurobiol Dis 2007;25:217-29.
23. Blanco-Aparicio C, Renner O, Leal JF, Carnero A. PTEN, more than the AKT pathway. Carcinogenesis 2007;28:1379-86.
24. Fuster JJ, Sanz-Gonzalez SM, Moll UM, Andres V. Classic and novel roles of p53: prospects for anticancer therapy. Trends Mol Med 2007;13:192-9.
25. de Jonge-Peeters SD, Kuipers F, de Vries EG, Vellenga E. ABC transporter expression in hematopoietic stem cells and the role in AML drug resistance. Crit Rev Oncol Hematol 2007;62:214-26.
26. Mimeault M, Hauke R, Batra SK. Recent advances on the molecular mechanisms involved in drug-resistance of cancer cells and novel targeting therapies. Clin Pharmacol Ther 29;2007 [Epub ahead of print]
27. Mimeault M, Pommery N, Henichart JP. New advances on prostate carcinogenesis and therapies: involvement of EGF-EGFR transduction system. Growth Factors 2003;21:1-14.
28. Mimeault M, Bonenfant D, Batra SK. New advances on the functions of epidermal growth factor receptor and ceramides in skin cell differentiation, disorders and cancers. Skin Pharmacol Physiol 2004;17:153-66
29. Mimeault M, Mehta PP, Hauke R, Batra SK. Functions of normal and malignant prostatic stem/progenitor cells in tissue regeneration and cancer progression and novel targeting therapies against advanced prostate cancers. Endocr Rev 2008;21. [Epub ahead of print]
30. Mimeault M, Batra SK. Interplay of distinct growth factors during epithelial-mesenchymal transition of cancer progenitor cells and molecular targeting as novel cancer therapies. Ann Oncol 2007;18:1605-19.
31. Mimeault M, Batra SK 2007 Functions of tumorigenic and migrating cancer progenitor cells in cancer progression and metastasis and their therapeutic implications. Cancer Metastasis Rev 26:203-14.
32. Mimeault M, Batra SK. Recent progress on tissue-resident adult stem cell biology and their therapeutic implications. Stem Cell Rev 2008;21; [Epub ahead of print].
33. Chen BY, Liu JY, Chang HH, Chang CP, Lo WY, Kuo WH et al. Hedgehog is involved in prostate basal cell hyperplasia formation and its progressing towards tumorigenesis. Biochem Biophys Res Commun 2007;357:1084-9.
34. Al-Hajj M, Clarke MF. Self-renewal and solid tumor stem cells. Oncogene 2004;23:7274-82.
35. Sell S. Stem cell origin of cancer and differentiation therapy. Crit Rev Oncol Hematol 2004;51:1-28
36. Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T. Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression. Nat Rev Cancer 2005;5:744-9.
37. Vescovi AL, Galli R, Reynolds BA. Brain tumour stem cells. Nat Rev Cancer 2006;6:425-36.
38. Massard C, Deutsch E, Soria JC. Tumour stem cell-targeted treatment: elimination or differentiation. Ann Oncol 2006;17:1620-4.
39. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005;65:10946-51.
40. Kurbel S. Selective reduction of estrogen receptor (ER) positive breast cancer occurrence by estrogen receptor modulators supports etiological distinction between ER positive and ER negative breast cancers. Med Hypotheses 2005;64:1182-7.
41. Li L, Neaves WB. Normal stem cells and cancer stem cells: the niche matters. Cancer Res 2006;66:4553-7.
42. Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, Gobel U et al. Brenner MK. A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA 2004;101:14228-33.
43. Rizo A, Vellenga E, de Haan G., Schuringa JJ. Signaling pathways in self-renewing hematopoietic and leukemic stem cells: do all stem cells need a niche? Hum Mol Genet 2006;2:R210-R219.
44. Liu S, Dontu G, Mantle ID, Patel S, Ahn NS, Jackson KW et al. Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res 2006;66:6063-71.
45. Beachy PA, Karhadkar SS, Berman DM. Tissue repair and stem cell renewal in carcinogenesis. Nature 2004;432:324-31.
46. Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR et al. Analysis of gene expression and chemoresistance of CD 133+ cancer stem cells in glioblastoma. Mol Cancer 2006;5:67.
47. Tso CL, Shintaku P, Chen J, Liu Q, Liu J, Chen Z et al. Primary glioblastomas express mesenchymal stem-like properties. Mol Cancer Res 2006;4:607-19.
48. Ho MM, Ng AV, Lam S, Hung JY. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res 2007;67:4827-33.
49. Fan X, Matsui W, Khaki L, Stearns D, Chun J, Li YM et al. Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res 2006;66:7445-52
50. Liu S, Dontu G, Wicha MS. Mammary stem cells, self-renewal pathways, and carcinogenesis. Breast Cancer Res 2005;7:86-95.
51. Sengupta A, Banerjee D, Chandra S, Banerji SK, Ghosh R, Roy R et al. Deregulation and cross talk among Sonic hedgehog, Wnt, Hox and Notch signaling in chronic myeloid leukemia progression. Leukemia 2007;21:949-55.
52. Karhadkar SS, Bova GS, Abdallah N, Dhara S, Gardner D, Maitra A et al. Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature 2006;431:707-12.
53. Mimeault M, Moore E, Moniaux N, Hénichart JP, Depreux P, Lin MF et al. Cytotoxic effects induced by a combination of cyclopamine and gefitinib, the selective hedgehog and epidermal growth factor receptor signaling inhibitors, in prostate cancer cells. Int J Cancer 2006;118:1022-31.
54. Mimeault M, Johansson SL, Venkatraman G, Moore E, Henichart JP, Depreux P et al. Combined targeting of epidermal growth factor receptor and hedgehog signaling by gefitinib and cyclopamine cooperatively improves the cytotoxic effects of docetaxel on metastatic prostate cancer cells. Mol Cancer Ther 2007;6:967-78.
55. Mimeault M, Venkatraman G, Johansson SL, Moore E, Henichart JP, Depreux P et al. Novel combination therapy against metastatic and androgen-independent prostate cancer by using gefitinib, tamoxifen and etoposide. Int J Cancer 2007;120:160-9.
56. Mimeault M, Mehta PP, Hauke R et al. Improvement of cytotoxic effects of mitoxantrone on hormone-refractory metastatic prostate cancer cells by co-targeting epidermal growth factor receptor and hedgehog signaling cascades. Growth Factors (In press)
57. Dancey JE, Chen HX. Strategies for optimizing combinations of molecularly targeted anticancer agents. Nat Rev Drug Discov 2006;5:649-59.
58. Ceschel S, Casotto V, Valsecchi MG, Tamaro P, Jankovic M, Hanau G et al. Survival after relapse in children with solid tumors: a follow-up study from the Italian off-therapy registry. Pediatr Blood Cancer 2006;47:560-6.
59. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006;444:756-60.
60. Chen MS, Woodward WA, Behbod F, Peddibhotla S, Alfaro MP, Buchholz TA et al. Wnt/beta-catenin mediates radiation resistance of Seal+ progenitors in an immortalized mammary gland cell line. J Cell Sci 2007;120:468-77.
61. Burke MJ, Walterhouse DO, Jacobsohn DA, Duerst RE, Kletzel M. Tandem high-dose chemotherapy with autologous peripheral hematopoietic progenitor cell rescue as consolidation therapy for patients with high-risk Ewing family tumors. Pediatr Blood Cancer 2007;49:196-8.
62. Schlemmer M, Wendtner CM, Falk M, Abdel-Rahman S, Licht T, Baumert J et al. Efficacy of consolidation high-dose chemotherapy with ifosfamide, carboplatin and etoposide (HD-ICE) followed by autologous peripheral blood stem cell rescue in chemosensitive patients with metastatic soft tissue sarcomas. Oncology 2006;71:32-9.
63. Lang P, Pfeiffer M, Muller I, Schumm M, Ebinger M, Koscielniak E et al. Haploidentical stem cell transplantation in patients with pediatric solid tumors: preliminary results of a pilot study and analysis of graft versus tumor effects. Klin Padiatr 2006;218:321-6.
64. Okada T, Ozawa K. Vector-producing tumor-tracking multipotent mesenchymal stromal cells for suicide cancer gene therapy. Front Biosci 2008;13:1887-91.
65. Ringden O. Immunotherapy by allogeneic stem cell transplantation. Adv Cancer Res 97C:25-60.
66. Avramova B, Jordanova M, Michailov G, Konstantinov D, Christosova I, Bobev D. Myeloablative chemotherapy with autologous peripheral blood stem cell transplantation in patients with poor-prognosis solid tumors - Bulgarian experience. J BUON 2006;11:433-8.
67. Yu JJ, Sun X, Yuan X, Lee JW, Snyder EY, Yu JS. Immunomodulatory neural stem cells for brain tumour therapy. Expert Opin Biol Ther 2006;6:1255-62.
68. Fodde R. Stem cells and metastatic cancer: fatal attraction? PLoS Med 2006;3:e482.
69. Mapara KY, Stevenson CB, Thompson RC, Ehtesham M. Stem cells as vehicles for the treatment of brain cancer. Neurosurg Clin N Am 2007;18:71-80.
70. Schmidt NO, Przylecki W, Yang W, Ziu M, Teng Y, Kim SU et al. Brain tumor tropism of transplanted human neural stem cells is induced by vascular endothelial growth factor. Neoplasia 2005;7:623-9.
71. Muller FJ, Snyder EY, Loring JF. Gene therapy: can neural stem cells deliver? Nat Rev Neurosci 2006;7:75-84.
72. Aboody KS, Bush RA, Garcia E, Metz MZ, Najbauer J, Justus KA et al. Development of a tumor-selective approach to treat metastatic cancer. PLoS ONE 2006;1:e23.
73. Ehtesham M, Kabos P, Kabosova A, Neuman T, Black KL, Yu JS. The use of interleukin 12-secreting neural stem cells for the treatment of intracranial glioma. Cancer Res 2002;62:5657-63.
74. Ehtesham M, Kabos P, Gutierrez MA, Chung NH, Griffith TS, Black KL et al. Induction of glioblastoma apoptosis using neural stem cell-mediated delivery of tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res 2002;62:7170-4.
75. Bregni M, Bernardi M, Ciceri F, Peccatori J. Allogeneic stem cell transplantation for the treatment of advanced solid tumors. Springer Semin Immunopathol 2004;26:95-108.
76. Small TN, Young JW, Castro-Malaspina H, Prockop S, Wilton A, Heller G et al. Intravenous busulfan and melphalan, tacrolimus, and short-course methotrexate followed by unmodified HLA-matched related or unrelated hematopoietic stem cell transplantation for the treatment of advanced hematologic malignancies. Biol Blood Marrow Transplant 2007;13:235-44.
77. Perez-Martinez A, Lassaletta A, Gonzalez-Vicent M, Sevilla J, Diaz MA, Madero L. High-dose chemotherapy with autologous stem cell rescue for children with high risk and recurrent medulloblastoma and supratentorial primitive neuroectodermal tumors. J Neurooncol 2005;71:33-8.
78. Corradini P, Tarella C, Zallio F, Dodero A, Zanni M, Valagussa P et al. Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia 2006;20:1533-8.
79. Oyan B, Koc Y, Ozdemir E, Kars A, Turker A, Tekuzman G et al. High dose sequential chemotherapy and autologous stem cell transplantation in patients with relapsed/refractory lymphoma. Leuk Lymphoma 2006;47:1545-52.
80. von Allmen D, Grupp S, Diller L, Marcus K, Ecklund K, Meyer J et al. Aggressive surgical therapy and radiotherapy for patients with high-risk neuroblastoma treated with rapid sequence tandem transplant. J Pediatr Surg 2005;40:936-41.
81. George RE, Li S, Medeiros-Nancarrow C, Neuberg D, Marcus K, Shamberger RC et al. High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update. J Clin Oncol 2006;24:2891-96.
82. Dillman RO, Barth NM, VanderMolen LA, Allen K, Beutel LD, Chico S. High-dose chemotherapy and autologous stem cell rescue for metastatic breast cancer: superior survival for tandem compared with single transplants. Am J Clin Oncol 2005;28:281-8.
83. Carella AM, Beltrami G, Corsetti MT, Nati S, Musto P, Scalzulli P et al. Reduced intensity conditioning for allograft after cytoreductive autograft in metastatic breast cancer. Lancet 2005;366:318-20.
84. Barfield RC, Hale GA, Burnette K, Behm FG, Knapp K, Eldridge P et al. Autologous transplantation of CD133 selected hematopoietic progenitor cells for treatment of relapsed acutely mphoblastic leukemia. Pediatr Blood Cancer 2007;48:349-353
85. Sora F, Piccirillo N, Chiusolo P, Laurenti L, Marra R, Bartolozzi F et al. Mitoxantrone, carboplatin, cytosine arabinoside, and methyl-prednisolone followed by autologous peripheral blood stem cell transplantation: a salvage regimen for patients with refractory or recurrent non-Hodgkin lymphoma. Cancer 2006;106:859-66.
86. Iwasaki Y, Nagata K, Nakanishi M, Natuhara A, Kubota Y, Ueda M et al. Double-cycle, high-dose ifosfamide, carboplatin, and etoposide followed by peripheral blood stem-cell transplantation for small cell lung cancer. Chest 2005;128:2268-73.
87. Matsubara H, Makimoto A, Higa T, Kawamoto H, Sakiyama S, Hosono A et al. A multidisciplinary treatment strategy that includes high-dose chemotherapy for metastatic retinoblastoma without CNS involvement. Bone Marrow Transplant 2005;35:763-6.
88. Hale GA. Autologous hematopoietic stem cell transplantation for pediatric solid tumors. Expert Rev Anticancer Ther 2005;5:835-46.
89. Frickhofen N, Berdel WE, Opri F, Haas R, Schneeweiss A, Sandherr M et al. Phase I/II trial of multicycle high-dose chemotherapy with peripheral blood stem cell support for treatment of advanced ovarian cancer. Bone Marrow Transplant 2006;38:493-9.
90. Bapat SA, Mali AM, Koppikar CB, Kurrey NK. Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res 2005;65:3025-9
91. Hermann PC, Huber SL, Herrler T, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. 2007;1 ed.; 313-23.
92. Hope KJ, Jin L, Dick JE. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol 2004;5:738-43.
93. Matsui W, Huff CA, Wang Q, Malehorn MT, Barber J, Tanhehco Y et al. Characterization of clonogenic multiple myeloma cells. Blood 2004;103:2332-6.
94. Hemmati HD, Nakano I, Lazareff JA, Masterman-Smith M, Geschwind DH, Bronner-Fraser M et al. Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci USA 2003;100:15178-83.
95. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T et al. Identification of human brain tumour initiating cells. Nature 2004;432:396-01.
96. Yuan X, Curtin J, Xiong Y, Liu G, Waschsmann-Hogiu S, Farkas DL et al. Isolation of cancer stem cells from adult glioblastoma multiforme. Oncogene 23:9392-400.
97. Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De Vitis S et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 2004;64:7011-21.
98. Al-Hajj M, Wicha MS, ito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003;100:3983-8.
99. Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini Det al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 2005;65:5506-11.
100. Patrawala L, Calhoun T, Schneider-Broussard R, Li H, Bhatia B, Tang S et al. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 2006;25:1696-708
101. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V et al. Identification of pancreatic cancer stem cells. Cancer Res 2007;67:1030-7.
102. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007;445:111-5.
103. Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA 2007;104:973-8.
104. Taylor MD, Poppleton H, Fuller C, Su X, Liu Y, Jensen P et al. Radial glia cells are candidate stem cells of ependymoma. Cancer Cell 2005;8:323-35.
105. Fang D, Nguyen TK, Leishear K, Finko R, Kulp AN, Hotz S et al. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 2005;65:9328-37.
106. Patrawala L, Calhoun T, Schneider-Broussard R, Zhou J, Claypool K, Tang DG. Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic. Cancer Res 2005;65:6207-19.
107. Tai MH, Chang CC, Kiupel M, Webster JD, Olson LK, Trosko JE. Oct4 expression in adult human stem cells: evidence in support of the stem cell theory of carcinogenesis. Carcinogenesis 2005;26:495-502.
108. Hadnagy A, Gaboury L, Beaulieu R, Balicki D. SP analysis may be used to identify cancer stem cell populations. Exp Cell Res 2006;312:3701-10.
109. Klein WM, Wu BP, Zhao S, Wu H, Klein-Szanto AJ, Tahan SR. Increased expression of stem cell markers in malignant melanoma. Mod Pathol 2007;20:102-7.
110. Immervoll H, Hoem D, Sakariassen PO, Steffensen OJ, Molven A. Expression of the "stem cell marker" CD133 in pancreas and pancreatic ductal adenocarcinomas. BMC Cancer 2008;8:48.
111. Wright MH, Calcagno AM, Salcido CD, Carlson MD, Ambudkar SV, Varticovski L. Brcal breast tumors contain distinct CD44+/CD24-and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res 2008;10:R10.
112. Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 2008;15:504-14.
113. Yang ZF, Ho DW, Ng MN, Lau CK, Yu WC, Ngai P et al. Significance of CD90(+) cancer stem cells in human liver cancer. Cancer Cell 2008;13:153-66.
114. Bhatia M, Bonnet D, Murdoch B, Gan OI, Dick JE. A newly discovered class of human hematopoietic cells with SCID-repopulating activity. Nat Med 1998;4:1038-45.
115. Wulf GG, Wang RY, Kuehnle I, Weidner D, Marini F, Brenner MK et al. A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood 2001;98:1166-73.
116. Rossi DJ, Bryder D, Weissman IL. Hematopoietic stem cell aging: Mechanism and consequence. Exp Gerontol 2007;42:385-90.
117. Haraguchi N, Utsunomiya T, Inoue H, Tanaka F, Mimori K, Barnard GF et al. Characterization of a side population of cancer cells from human gastrointestinal system. Stem Cells 2006;24:506-13.
118. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002;2:442-54.
119. Rafii S, Lyden D, Benezra R, Hattori K, Heissig B. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat Rev Cancer 2002;2:826-35.
120. Orimo A, Weinberg RA. Stromal fibroblasts in cancer: A novel tumor-promoting cell type. Cell Cycle 2006;5:1597-601.
121. Ganss R. Tumor stroma fosters neovascularization by recruitment of progenitor cells into the tumor bed. J Cell Mol Med 2006;10: 857-65.
122. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005;438:820-7.
123. Bruno S, Bussolati B, Grange C, Collino F, Graziano ME, Ferrando U et al. CD133+ renal progenitor cells contribute to tumor angiogenesis. Am J Pathol 2006;169:2223-35.
124. Dalerba P, Cho RW, Clarke MF. Cancer stem cells: models and concepts. Annu Rev Med 2007;58:267-84.
125. Chen L, Shen R, Ye Y, Pu XA, Liu X, Duan W et al. Precancerous stem cells have the potential for both benign and malignant differentiation. PLoS ONE 2007;2:e293.
126. Cobaleda C. Gutierrez-Cianca N, Perez-Losada J, Flores T, Garcia-Sanz R, Gonzalez M et al. A primitive hematopoietic cell is the target for the leukemic transformation in human philadelphia-positive acute lymphoblastic leukemia. Blood 2000;95:1007-13.
127. Jamieson CH, Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 2004;351:657-67.
128. Frankfurt O, Tallman MS. Growth factors in leukemia. J Natl Compr Cane Netw 2007;5:203-15.
129. Matthews RH, Emami M, Connaghan DG, Holland HK, Morris LE. Home administration of high-dose oral busulfan in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant 2007;39:397-400.
130. Petit I, Szyper-Kravitz M, Nagler A, Lahav M, Peled A, Habler L et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol 2002;3:687-94.
131. De Clercq E. Potential clinical applications of the CXCR4 antagonist bicyclam AMD3100. Mini Rev Med Chem 2005;5:805-24.
132. Bonanno G, Perillo A, Rutella S, De Ritis DG, Mariotti A, Marone M et al. Clinical isolation and functional characterization of cord blood CD133+ hematopoietic progenitor cells. Transfusion 2004;44:1087-97.
133. Rollini P, Kaiser S, Faes-van't HE, Kapp U, Leyvraz S. Long-term expansion of transplantable human fetal liver hematopoietic stem cells. Blood 2004;103:1166-70.
134. Brunstein CG, Setubal DC, Wagner JE. Expanding the role of umbilical cord blood transplantation. Br J Haematol 2007;137:20-35.
135. Cohen Y, Nagler A. Umbilical cord blood transplantation - how, when and for whom? Blood Rev 2004;18:167-79.
136. Aoudjhane M, Labopin M, Gorin NC, Shimoni A, Ruutu T, Kolb HJ et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia 2005;19: 2304-12.
137. Bhattacharya D, Rossi DJ, Bryder D, Weissman IL. Purified hematopoietic stem cell engraftment of rare niches corrects severe lymphoid deficiencies without host conditioning. J Exp Med 2006;203:73-85.
138. Hesdorffer C, Ayello J, Ward M, Kaubisch A, Vahdat L, Balmaceda C et al. Phase I trial of retroviral-mediated transfer of the human MDR1 gene as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation. J Clin Oncol 1998;16:165-72.
139. Hu Y, Swerdlow S, Duffy TM, Weinmann R, Lee FY, Li S. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice. Proc Natl Acad Sci U S A 2006;103:16870-5.
140. Burger H, Nooter K. Pharmacokinetic resistance to imatinib mesylate: role of the ABC drug pumps ABCG2 (BCRP) and ABCB1 (MDR1) in the oral bioavailability of imatinib. Cell Cycle 2004;3:1502-5.
141. Jiang X, Zhao Y, Smith C, Gasparetto M, Turhan A, Eaves A et al. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia 2007;21:926-35.
142. Angstreich GR, Matsui W, Huff CA Vala MS, Barber J, Hawkins AL et al. Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitors. Br J Haematol 2005;130:373-81.
143. Holtz M, Forman SJ, Bhatia R. Growth factor stimulation reduces residual quiescent chronic myelogenous leukemia progenitors remaining after imatinib treatment. Cancer Res 2007;67:1113-20.
144. Lowenberg B, Griffin JD, Tallman MS. Acute myeloid leukemia and acute promyelocytic leukemia. Hematology Am Soc Hematol Educ Program 2003;82-101.
145. Zhao ZG, Liang Y, Li K, Li WM, Li QB, Chen ZC et al. Phenotypic and functional comparison of mesenchymal stem cells derived from the bone marrow of normal adults and patients with hematologic malignant diseases. Stem Cells Dev 2007;16:637-48.
146. Helman LJ, Meltzer P. chanisms of sarcoma development. Nat Rev Cancer 2003;3:685-94.
147. Mackall CL, Meltzer PS, Helman LJ. Focus on sarcomas. Cancer Cell 2002;2:175-8.
148. de Silva CM, Reid R. Gastrointestinal stromal tumors (GIST): C-kit mutations, CD117 expression, differential diagnosis and targeted cancer therapy with Imatinib. Pathol Oncol Res 2003;9:13-9
149. Gibbs CP, Kukekov VG, Reith JD, Tchigrinova O, Suslov ON, Scott EW et al. Stem-like cells in bone sarcomas: implications for tumorigenesis. Neoplasia 2005;7:967-76.
150. Ogasawara N, Tsukamoto T, Inada K, Mizoshita T, Ban N, Yamao K et al. Frequent c-Kit gene mutations not only in gastrointestinal stromal tumors but also in interstitial cells of Cajal in surrounding normal mucosa. Cancer Lett 2005;230:199-210.
151. Min KW, Leabu M. Interstitial cells of Cajal (ICC) and gastrointestinal stromal tumor (GIST): facts, speculations, and myths. J Cell Mol Med 2006;10:995-13.
152. Antonescu CR. Gastrointestinal stromal tumor (GIST) pathogenesis, familial GIST, and animal models. Semin Diagn Pathol 2006;23:63-9.
153. Tolar J, Nauta AJ, Osborn MJ, Panoskaltsis Mortari A, McElmurry RT, Bell S et al. Sarcoma derived from cultured mesenchymal stem cells. Stem Cells 2007;25:371-9.
154. Riggi N, Cironi L, Provero P, Suvà ML, Kaloulis K, Garcia-Echeverria C et al. Development of Ewing's sarcoma from primary bone marrow-derived mesenchymal progenitor cells. Cancer Res 2005;65:11459-68.
155. Tirode F, Laud-Duval K, Prieur A, Delorme B, Charbord P, Delattre O. Mesenchymal stem cell features of Ewing tumors. Cancer Cell 2007;11:421-29.
156. Kyritsis AP, Tsokos M, Triche TJ, Chader GJ. Retinoblastoma-origin from a primitive neuroectodermal cell? Nature 1984;307: 471-3.
157. Dyer MA, Bremner R. The search for the retinoblastoma cell of origin. Nat Rev Cancer 2005;5:91-101.
158. Zhong X, Li Y, Peng F, Huang B, Lin J, Zhang W et al. Identification of tumorigenic retinal stem-like cells in human solid retinoblastomas. Int J Cancer 2007;121:2125-31.
159. Seigel GM, Hackam AS, Ganguly A, Mandell LM, Gonzalez-Fernandez F. Human embryonic and neuronal stem cell markers in retinoblastoma. Mol Vis 2007;13:823-32.
160. Chintagumpala M, Chevez-Barrios P, Paysse EA, Plon SE, Hurwitz R. Retinoblastoma: review of current management. Oncologist 2007;12:1237-46.
161. Koleva M, Kappler R, Vogler M, Herwig A, Fulda S, Hahn H. Pleiotropic effects of sonic hedgehog on muscle satellite cells. Cell Mol Life Sci 2005;62:1863-70.
162. Pollett JB, Corsi KA, Weiss KR, Cooper GM, Barry DA, Gharaibeh B et al. Malignant transformation of multipotent muscle-derived cells by concurrent differentiation signals. Stem Cells 2007;25:2302-11.
163. Langenau DM, Keefe MD, Storer NY, Guyon JR, Kutok JL, Le X et al. Effects of RAS on the genesis of embryonal rhabdomyosarcoma. Genes Dev 2007;21:1382-95.
164. Linardic CM, Downie DL, Qualman S, Bentley RC, Counter CM. Genetic modeling of human rhabdomyosarcoma. Cancer Res 2005;65:4490-5.
165. Tataria M, Quarto N, Longaker MT, Sylvester KG. Absence of the p53 tumor suppressor gene promotes osteogenesis in mesenchymal stem cells. J Pediatr Surg 41:2006;624-32.
166. Thomas D, Kansara M. Epigenetic modifications in osteogenic differentiation and transformation. J Cell Biochem 2006;98:757-69.
167. Aerts I, Pacquement H, Doz F, Mosseri V, Desjardins L, Sastre X et al. Outcome of second malignancies after retinoblastoma: a retrospective analysis of 25 patients treated at the Institut Curie. Eur J Cancer 2004;40:1522-9.
168. Mittal R, Al AS, Sahar O, Behbehani AM. Ewing's sarcoma as second malignant neoplasm after retinoblastoma: a case report. Med Princ Pract 2008;17:84-5.
169. Dadia S, Grimer R 2007 Characteristics, diagnosis and treatment of bone and soft tissue sarcomas. Br J Hosp Med (Lond) 68:589-593
170. Sleijfer S, Wiemer E, Verweij J. Drug Insight: gastrointestinal stromal tumors (GIST) - the solid tumor model for cancer-specific treatment. Nat Clin Pract Oncol 2008;5:102-11.
171. Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008;26:626-32.
172. Saab R, Bills JL, Miceli AP, Anderson CM, Khoury JD, Fry DW et al. Pharmacologic inhibition of cyclin-dependent kinase 4/6 activity arrests proliferation in myoblasts and rhabdomyosarcoma-derived cells. Mol Cancer Ther 2006;5:1299-308.
173. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med 2004;351:998-1012.
174. Ruiter D, Bogenrieder T, Elder D, Herlyn M. Melanoma-stroma interactions: structural and functional aspects. Lancet Oncol 2002;3:35-43.
175. Pinnix CC, Herlyn M. The many faces of Notch signaling in skin-derived cells. Pigment Cell Res 2007;20:458-65.
176. den Brok MH, Nierkens S, Figdor CG, Ruers TJ, Adema GJ. Dendritic cells: tools and targets for antitumor vaccination. Expert Rev Vaccines 2005;4:699-710.
177. Sigalotti L, Covre A, Zabierowski S, Himes B, Colizzi F, Natali PG et al. Cancer testis antigens in human melanoma stem cells: Expression, distribution, and methylation status. J Cell Physiol 2008;215:287-91.
178. Li H, Alizadeh H, Niederkorn JY. Differential expression of chemokine receptors on uveal melanoma cells and their metastases. Invest Ophthalmol Vis Sci 2008;49:636-43.
179. Albini A, Fassina G, Nicolo M, Dell'Eva R, Vené R, Cammarota R et al. Inhibition of a vascular ocular tumor growth by IL-12 gene transfer. Clin Exp Metastasis 2007;24:485-93.
180. Triozzi PL, Eng C, Singh AD. Targeted therapy for uveal melanoma. Cancer Treat Rev 2008.
181. Marshall JC, Nantel A, Blanco P, Ash J, Cruess SR, Burnier MN, Jr. Transcriptional profiling of human uveal melanoma from cell lines to intraocular tumors to metastasis. Clin Exp Metastasis 2007;24:353-62.
182. Mallikarjuna K, Pushparaj V, Biswas J, Krishnakumar S. Expression of epidermal growth factor receptor, ezrin, hepatocyte growth factor, and c-Met in uveal melanoma: an immunohistochemical study. Curr Eye Res 2007;32:281-90.
183. Marshall JC, Fernandes BF, Di Cesare S, et al. The use of a cyclooxygenase-2 inhibitor (Nepafenac) in an ocular and metastatic animal model of uveal melanoma. Carcinogenesis 28:2053-8.
184. Di Cesare S, Marshall JC, Fernandes BF, Logan P, Antecka E, Filho VB et al. In vitro characterization and inhibition of the CXCR4/CXCL12 chemokine axis in human uveal melanoma cell lines. Cancer Cell Int 2007;7:17.
185. Mannelli M, Simi L, Gagliano MS, Opocher G, Ercolino T, Becherini L et al. Genetics and biology of pheochromocytoma. Exp Clin Endocrinol Diabetes 2007;115:160-5.
186. Nakagawara A, Ohira M. Comprehensive genomics linking between neural development and cancer: neuroblastoma as a model. Cancer Lett 2004;204:213-24.
187. Ross RA, Spengler BA. Human neuroblastoma stem cells. Semin Cancer Biol 2007;17:241-7.
188. Sanai N, varez-Buylla A, Berger MS. Neural stem cells and the origin of gliomas. N Engl J Med 2005;353:811-22.
189. Eberhart CG. In search of the medulloblast: neural stem cells and embryonal brain tumors. Neurosurg Clin N Am 2007;18:59.
190. Baehring JM. An update on oligodendroglial neoplasms. Curr Opin Neurol 2005;18:639-44.
191. Alexander A, Murtha A, Abdulkarim B, Mehta V, Wheatley M, Murray B et al. Prognostic significance of serial magnetic resonance spectroscopies over the course of radiation therapy for patients with malignant glioma. Clin Invest Med 2006;29:301-11.
192. Thompson MC, Fuller C, Hogg TL, Dalton J, Finkelstein D, Lau CC et al. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol 2006;24:1924-31.
193. Lubensky IA, Vortmeyer AO, Kim S, Lonser RR, Park DM, Ikejiri B et al. Identification of tumor precursor cells in the brains of primates with radiation-induced de novo glioblastoma multiforme. Cell Cycle 2006;5:452-6.
194. Zhu Y, Guignard F, Zhao D, Liu L, Burns DK, Mason RP et al. Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. Cancer Cell 2005;8:119-30.
195. Clement V, Sanchez P, de Tribolet N, Radovanovic I, Altaba A. HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Curr Biol 2007;17:165-72.
196. Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner B et al. A perivascular niche for brain tumor stem cells. Cancer Cell 2007;11:69-82.
197. Seigel GM, Campbell LM, Narayan M, Gonzalez-Fernandez F. Cancer stem cell characteristics in retinoblastoma. Mol Vis 2005;11:729-37.
198. Alison MR. Liver cancer: a disease of stem cells? Panminerva Med 2006;48:165-74.
199. Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, Dinulescu DM, Connolly D, Foster R et al. Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian inhibiting substance responsiveness. Proc Natl Acad Sci USA 2006;103:11154-9.
200. Chiba T, Kita K, Zheng YW, Yokosuka O, Saisho H, Iwama A et al. Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology 2006;44:240-51.
201. Haraguchi N, Inoue H, Tanaka F, Mimori K, Utsunomiya T, Sasaki A et al. Cancer stem cells in human gastrointestinal cancers. Hum Cell 2006;19:24-9.
202. Grichnik JM, Burch JA, Schulteis RD, Shan S, Liu J, Darrow TL et al. Melanoma, a tumor based on a mutant stem cell? J Invest Dermatol 2006;126:142-53.
203. Gu G, Yuan J, Wills M, Kasper S. Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo. Cancer Res 2007;67:4807-15.
204. Maitland NJ, Bryce SD, Stower MJ, Collins AT. Prostate cancer stem cells: a target for new therapies. Ernst Schering Found Symp Proc 2006;5:155-79.
205. Perillo A, Bonanno G, Pierelli L, Rutella S, Scambia G, Mancuso S. Stem cells in gynecology and obstetrics. Panminerva Med 2004;46:49-59.
206. Feldmann G, Dhara S, Fendrich V, Bedja D, Beaty R, Mullendore M et al. Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res 2007;67:2187-96.
207. Schrama D, Reisfeld RA, Becker JC. Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov 2006;5:147-59.
208. Nobili S, Landini I, Giglioni B, Mini E. Pharmacological strategies for overcoming multidrug resistance. Curr Drug Targets 2006;7:861-79.
209. Schatzlein AG. Delivering cancer stem cell therapies - a role for nanomedicines? Eur J Cancer 2006;42:1309-15.
210. Thorne SH. Strategies to achieve systemic delivery of therapeutic cells and microbes to tumors. Expert Opin Biol Ther 2007;7:41-51.